Vanda Pharmaceuticals
$14.399876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$14.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.10 (-0.69%) Today
$0.00 (0.00%) As of 12:00 PM UTC after-hours
Why Robinhood?
You can buy or sell VNDA and other stocks, options, and ETFs commission-free!
About VNDA
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC. The listed name for VNDA is Vanda Pharmaceuticals Inc. Common Stock.
CEO
Mihael Hristos Polymeropoulos
Employees
284
Headquarters
Washington, District of Columbia
Founded
2002
Market Cap
774.79M
Price-Earnings Ratio
41.22
Dividend Yield
—
Average Volume
452.11K
High Today
$14.88
Low Today
$14.17
Open Price
$14.29
Volume
380.00K
52 Week High
$14.88
52 Week Low
$7.12
Collections
VNDA Earnings
$0.00
$0.09
$0.19
$0.28
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 23, After Hours